Navigation Links
Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28
Date:6/27/2017

TEL AVIV, Israel, June 27, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that the Company will ring The Nasdaq Stock Market Opening Bell in New York, NY on Wednesday, June 28, 2017 in honor of its initial public offering (IPO) of American Depository Shares (ADSs) listed on the Nasdaq Capital Market in March 2017.

Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, stated, "We're proud to celebrate the successful uplisting to the Nasdaq Capital Market as Therapix builds recognition in the U.S. markets to grow exposure to a broader and more diverse investor audience. As we ring the opening bell, I would also like to take this moment to acknowledge and thank the employees, investors and partners who have supported Therapix in our journey thus far. With Therapix running two U.S. clinical studies in 2017 and data on one of them to be released this year, today's celebration comes at a landmark point in our timeline."

A live webcast of The Nasdaq Stock Market Opening Bell ceremony will be available at https://livestream.com/nasdaq/live and also on the Investor Relations portion of Therapix's website at www.therapixbio.com.

Therapix began trading on the Nasdaq Capital Market on March 22, 2017, under the symbol "TRPX".

About Therapix Biosciences

Therapix Biosciences Ltd. (Nasdaq: TRPX) is a specialty clinical-stage pharmaceutical company focused on developing technologies and therapeutics based on cannabinoid pharmaceuticals. The Company's clinical pipeline assets follow a de-risked 505(b)(2) regulatory pathway benefitting from Therapix's unique proprietary formulations based on repurposing an FDA approved synthetic cannabinoid (dronabinol). Therapix's lead compound, THX-TS01, is currently in Phase 2 clinical trials for Tourette's Syndrome and the Company intends to initiate a Phase 1 clinical study of THX-ULD01 for the treatment of Mild Cognitive Impairment, for which no FDA-approved therapies currently exist. Please visit our website for more information at www.therapixbio.com.

Contacts

Josh Blacher
Chief Financial Officer
josh@therapixbio.com

Tirth Patel (investors)
Edison Group
tpatel@edisongroup.com


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therapix-biosciences-to-ring-the-nasdaq-stock-market-opening-bell-on-june-28-300480633.html


'/>"/>
SOURCE Therapix Biosciences Ltd
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June
2. Therapix Biosciences Ltd. Announces Full Exercise of Underwriters Over-Allotment Option
3. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
4. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
5. Therapix Biosciences Provides Portfolio Update
6. The Israeli Pharma Company Therapix, is Joined by Five Internationally Renowned Experts, From Israel and the World, in the Field of Psychiatry and Tourette
7. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
8. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
9. Pressure BioSciences, Inc. Discusses Research Market, Goals and Milestones for First Half of 2017 in New SNNLive Video Interview with StockNewsNow.com
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
11. How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):